1. At a Glance – The Comeback Kid with a GST Headache
₹39 stock price. ₹2,138 crore market cap. Quarterly sales of ₹484 crore. PAT of ₹28 crore. Quarterly EPS ₹0.50. TTM EPS ₹1.82. P/E around 28. ROCE 15.1%. ROE 11.8%. Debt-to-equity just 0.13.
And yet the stock is down 29% in one year and 14% in the last three months.
Welcome to Morepen Laboratories Ltd, a company that dominates Montelukast with 70% market share, rules Loratadine at 69%, and still manages to look like a mid-cap struggler in the stock market.
Q3 FY26 numbers (Dec 2025 quarter) show sales of ₹484 crore — highest in the last four quarters — and PAT of ₹28 crore. OPM back to 10%. But then you see a ₹117.94 crore GST show cause notice (stay granted by High Court), a QIP of ₹200 crore, and a business restructuring where medical devices are being hived off into a subsidiary.
Is this a clean pharma turnaround story?
Or a complicated family-owned pharma saga with a medical device side hustle?
Let’s open the lab coat and see what’s brewing.
2. Introduction – From Penny Stock to Pharma Contender?
Morepen is not a new kid on the Dalal Street block. It has been around for decades, survived the early 2000s pharma debt disasters, and quietly rebuilt itself.
Today it operates across:
- APIs
- Finished formulations
- OTC products under Dr. Morepen
- Medical devices (glucometers, BP monitors, strips)
It claims leadership in 6 APIs globally. Montelukast? 70%. Loratadine? 69%. Desloratadine? 49%.
That’s not small talk. That’s global dominance in anti-allergy and respiratory molecules.
But here’s the twist.
Despite being a volume leader, profitability isn’t blockbuster-level. TTM OPM is 8%. ROE is 11.8%. This isn’t Divi’s Labs territory. This is mid-tier grinder pharma.
And now management says: target ₹5,000 crore revenue by 2030.
Current revenue? ₹1,787 crore (TTM).
So they want to nearly triple in 5 years.
Ambitious? Yes.
Impossible? Not necessarily.
Easy? Absolutely not.
3. Business Model – WTF Do They Even Do?
Let’s simplify this for the lazy but intelligent investor.
